Abstract:NanomedicineVol. 9, No. 8 EditorialRecent progress in multidrug delivery to cancer cells by liposomesRan Mo, Tianyue Jiang & Zhen GuRan MoJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27695, USAMolecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USAState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China, Tianyue JiangJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27695, USAMolecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USAState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China & Zhen GuAuthor for correspondence: E-mail Address: zgu@email.unc.eduJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27695, USAMolecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USAPublished Online:14 Aug 2014https://doi.org/10.2217/nnm.14.62AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: chemotherapyco-deliverycombination cancer therapydrug deliverygene therapyliposomeprotein therapyReferences1 Bangham AD, Standish MM, Watkins JC et al. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13(1), 238–252 (1965).Crossref, Medline, CAS, Google Scholar2 Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine 8(9), 1509–1528 (2013).Link, CAS, Google Scholar3 Wang B, Galliford CV, Low PS. Guiding principles in the design of ligand-targeted nanomedicines. Nanomedicine 9(2), 313–330 (2014).Link, CAS, Google Scholar4 Mayer LD, Harasym TO, Tardi PG et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 5(7), 1854–1863 (2006).Crossref, Medline, CAS, Google Scholar5 Batist G, Gelmon KA, Chi KN et al. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res. 15(2), 692–700 (2009).Crossref, Medline, CAS, Google Scholar6 Feldman EJ, Lancet JE, Kolitz JE et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Oncol. 29(8), 979–985 (2011).Crossref, Medline, CAS, Google Scholar7 Feldman EJ, Kolitz JE, Trang JM et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk. Res. 36(10), 1283–1289 (2012).Crossref, Medline, CAS, Google Scholar8 Wong MY, Chiu GN. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine 7(6), 834–840 (2011).Crossref, Medline, CAS, Google Scholar9 Zucker D, Andriyanov AV, Steiner A et al. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. J. Controlled Release 160(2), 281–289 (2012).Crossref, Medline, CAS, Google Scholar10 Ong JC, Sun F, Chan E. Development of stealth liposome coencapsulating doxorubicin and fluoxetine. J. Liposome Res. 21(4), 261–271 (2011).Crossref, Medline, CAS, Google Scholar11 Sawant RR, Vaze OS, Rockwell K, Torchilin VP..Palmitoyl ascorbate-modified liposomes as nanoparticle platform for ascorbate-mediated cytotoxicity and paclitaxel co-delivery. Eur. J. Pharm. Biopharm. 75(3), 321–326 (2010).Crossref, Medline, CAS, Google Scholar12 Maitani Y, Saito H, Seishi Y et al. A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse. J. Drug Target. 20(10), 873–882 (2012).Crossref, Medline, CAS, Google Scholar13 Zhang YF, Wang JC, Bian DY et al. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur. J. Pharm. Biopharm. 74(3), 467–473 (2010).Crossref, Medline, CAS, Google Scholar14 Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 18(9), 1650–1656 (2010).Crossref, Medline, CAS, Google Scholar15 Shim G, Han SE, Yu YH et al. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J. Controlled Release 155(1), 60–66 (2011).Crossref, Medline, CAS, Google Scholar16 Kang SH, Cho HJ, Shim G et al. Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy. Pharm. Res. 28(12), 3069–3078 (2011).Crossref, Medline, CAS, Google Scholar17 Xiao W, Chen X, Yang L et al. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome. Int. J. Pharm. 393(1–2), 119–126 (2010).Crossref, Medline, CAS, Google Scholar18 Zhang Y, Schwerbrock NMJ, Rogers AB et al. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol. Ther. 21(8), 1559–1569 (2013).Crossref, Medline, CAS, Google Scholar19 Zhang M, Garbuzenko OB, Reuhl KR, Rodriguez-Rodriguez L, Minko T., Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. Nanomedicine 7(2), 185–197 (2012).Link, CAS, Google Scholar20 Sochanik A, Mitrus I, Smolarczyk R et al. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent. Arch. Immunol. Ther. Exp. (Warsz) 58(3), 235–245 (2010).Crossref, Medline, CAS, Google Scholar21 Koo YT, Falcao C, Torchilin VP. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol. Pharm. 6(3), 971–977 (2009).Crossref, Medline, Google Scholar22 Jiang T, Mo R, Bellotti A et al. Gel-liposome-mediated co-delivery of anticancer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy. Adv. Funct. Mater. 24(16), 2295–2304 (2014).Crossref, CAS, Google Scholar23 Wu GH, Milkhailovsky A, Khant HA et al. Remotely triggered liposome release by near-infrared light absorption via hollow gold nanoshells. J. Am. Chem. Soc. 130(26), 8175–8177 (2008).Crossref, Medline, CAS, Google Scholar24 Mo R, Jiang T, Gu Z. Enhanced anticancer efficacy by ATP-mediated liposomal. drug delivery. Angew. Chem. Int. Ed. 53(23), 5815–5820 (2014).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByEngineering Escherichia coli Nissle 1917 as a microbial chassis for therapeutic and industrial applicationsBiotechnology Advances, Vol. 67Engineered Extracellular Vesicles with Compound-Induced Cargo Delivery to Solid Tumors27 May 2023 | International Journal of Molecular Sciences, Vol. 24, No. 11ZnO Nanorods Create a Hypoxic State with Induction of HIF-1 and EPAS1, Autophagy, and Mitophagy in Cancer and Non-Cancer Cells9 April 2023 | International Journal of Molecular Sciences, Vol. 24, No. 8Amphiphilic Polypeptides Obtained by Post-Polymerization Modification of Poly-l-Lysine as Systems for Combined Delivery of Paclitaxel and siRNA21 April 2023 | Pharmaceutics, Vol. 15, No. 4Lipid Nanocarriers for Breast Cancer Treatment14 December 2022pH-Responsive Drug Delivery Nanoplatforms as Smart Carriers of Unsymmetrical Bisacridines for Targeted Cancer Therapy6 January 2023 | Pharmaceutics, Vol. 15, No. 1Chitosan-Boric Acid Scaffolds for Doxorubicin Delivery in the Osteosarcoma Treatment6 November 2022 | Polymers, Vol. 14, No. 21Nanocarriers for intracellular co-delivery of proteins and small-molecule drugs for cancer therapy6 September 2022 | Frontiers in Bioengineering and Biotechnology, Vol. 10Congo Red as a Supramolecular Carrier System for Doxorubicin: An Approach to Understanding the Mechanism of Action11 August 2022 | International Journal of Molecular Sciences, Vol. 23, No. 16Carbohydrates based stimulus responsive nanocarriers for cancer-targeted chemotherapy: a review of current practices8 June 2022 | Expert Opinion on Drug Delivery, Vol. 19, No. 6Composite Materials Based on Gelatin and Iron Oxide Nanoparticles for MRI Accuracy12 May 2022 | Materials, Vol. 15, No. 10Zinc Oxide Nanoparticles Ameliorate Dimethylnitrosamine-Induced Renal Toxicity in Rat2 December 2021 | Applied Biochemistry and Biotechnology, Vol. 194, No. 4Multifunctional carbon dot anchored halloysite nanotube: Nanovehicle for cisplatin drug release, cytotoxicity on breast cancer cells and DNA binding studiesChemical Data Collections, Vol. 38Doxorubicin Release from Bovine Serum Albumin Microparticles11 February 2022 | Pharmaceutical Chemistry Journal, Vol. 55, No. 11A review of Nigella sativa and its active principles as anticancer agentsPlant Pollen Grains: A Move Towards Green Drug and Vaccine Delivery Systems15 May 2021 | Nano-Micro Letters, Vol. 13, No. 1Autonomously Propelled Colloids for Penetration and Payload Delivery in Complex Extracellular Matrices6 October 2021 | Micromachines, Vol. 12, No. 10Polymer incorporated magnetic nanoparticles: Applications for magnetoresponsive targeted drug deliveryMaterials Science and Engineering: B, Vol. 272A DFT Study of Graphitic Carbon Nitride as Drug Delivery Carrier for Flutamide (Anticancer Drug)21 June 2021 | Journal of Computational Biophysics and Chemistry, Vol. 20, No. 04Lignin, lipid, protein, hyaluronic acid, starch, cellulose, gum, pectin, alginate and chitosan-based nanomaterials for cancer nanotherapy: Challenges and opportunitiesInternational Journal of Biological Macromolecules, Vol. 178Delivery of eupenifeldin via polymer-coated surgical buttresses prevents local lung cancer recurrenceJournal of Controlled Release, Vol. 331Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics26 January 2021 | Biomedicines, Vol. 9, No. 2Material and strategies used in oncology drug deliveryAlginate-based hydrogels as drug delivery vehicles in cancer treatment and their applications in wound dressing and 3D bioprinting13 March 2020 | Journal of Biological Engineering, Vol. 14, No. 1In-vitro and in-vivo evaluation of polymeric microsphere formulation for colon targeted delivery of 5-fluorouracil using biocompatible natural gum katiraInternational Journal of Biological Macromolecules, Vol. 158Ratiometric delivery of doxorubicin and berberine by liposome enables superior therapeutic index than DoxilⓇAsian Journal of Pharmaceutical Sciences, Vol. 15, No. 3pH-responsive nanomicelles of poly(ethylene glycol)-poly(ε-caprolactone)-poly(L-histidine) for targeted drug delivery11 November 2019 | Journal of Biomaterials Science, Polymer Edition, Vol. 31, No. 3Bifidobacterium spp: the promising Trojan Horse in the era of precision oncologyNealie Ngo, Khalil Choucair, Justin F Creeden, Hanan Qaqish, Krupa Bhavsar, Chantal Murphy, Kendra Lian, Mary T Albrethsen, Laura Stanbery, Richard C Phinney, F Charles Brunicardi, Lance Dworkin & John Nemunaitis31 October 2019 | Future Oncology, Vol. 15, No. 33Understanding the Nano-bio Interfaces: Lipid-Coatings for Inorganic Nanoparticles as Promising Strategy for Biomedical Applications15 May 2019 | Frontiers in Chemistry, Vol. 7Recent Advances in Chitosan-Based Systems for Delivery of Anticancer Drugs6 March 2020Combinational delivery therapies of nucleic acids for cancer treatmentDual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance11 March 2019 | Drug Delivery, Vol. 26, No. 1Controlled drug delivery vehicles for cancer treatment and their performance16 March 2018 | Signal Transduction and Targeted Therapy, Vol. 3, No. 1Recent Advances in Self-assembled Nano-therapeutics26 December 2017 | Chinese Journal of Polymer Science, Vol. 36, No. 3Mixed Liposome Approach for Ratiometric and Sequential Delivery of Paclitaxel and Gemcitabine2 October 2017 | AAPS PharmSciTech, Vol. 19, No. 2Liposome-targeted delivery for highly potent drugs17 February 2017 | Artificial Cells, Nanomedicine, and Biotechnology, Vol. 45, No. 8Liposome-Coated Persistent Luminescence Nanoparticles as Luminescence Trackable Drug Carrier for Chemotherapy15 June 2017 | Analytical Chemistry, Vol. 89, No. 13Zinc oxide nanoparticles antagonize the effect of Cetuximab on head and neck squamous cell carcinoma in vitro11 May 2017 | Cancer Biology & Therapy, Vol. 18, No. 7Nanoformulations for combination or cascade anticancer therapyAdvanced Drug Delivery Reviews, Vol. 115Liposome-based drug co-delivery systems in cancer cellsMaterials Science and Engineering: C, Vol. 71Zinc oxide nanoparticles as a novel anticancer approach; in vitro and in vivo evidence24 January 2017 | Clinical and Experimental Pharmacology and Physiology, Vol. 44, No. 2Nanoscale Drugs: A Key to Revolutionary Progress in Pharmacy and Healthcare2 December 2016Recent progress in nanomedicine-based combination cancer therapy using a site-specific co-delivery strategy1 January 2017 | Biomaterials Science, Vol. 5, No. 8DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting17 October 2016 | Drug Delivery, Vol. 23, No. 9Co-delivery of drugs and plasmid DNA for cancer therapyAdvanced Drug Delivery Reviews, Vol. 98Co-delivery of chemotherapeutics and proteins for synergistic therapyAdvanced Drug Delivery Reviews, Vol. 98Recent advances of cocktail chemotherapy by combination drug delivery systemsAdvanced Drug Delivery Reviews, Vol. 98A poly(ascorbyl acrylate)-containing nanoplatform with anticancer activity and the sequential combination therapy with its loaded paclitaxel1 January 2016 | Journal of Materials Chemistry B, Vol. 4, No. 40Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatmentBiomaterials, Vol. 73Furin-Mediated Sequential Delivery of Anticancer Cytokine and Small-Molecule Drug Shuttled by Graphene15 December 2014 | Advanced Materials, Vol. 27, No. 6Development of individualized anti-metastasis strategies by engineering nanomedicines1 January 2015 | Chemical Society Reviews, Vol. 44, No. 17Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells1 January 2015 | Journal of Materials Chemistry B, Vol. 3, No. 8 Vol. 9, No. 8 STAY CONNECTED Metrics Downloaded 458 times History Published online 14 August 2014 Published in print June 2014 Information© Future Medicine LtdKeywordschemotherapyco-deliverycombination cancer therapydrug deliverygene therapyliposomeprotein therapyFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download

Abstract:Cationic liposomes (CLs) have been regarded as the most promising gene delivery vectors for decades with the advantages of excellent biodegradability, biocompatibility, and high nucleic acid encapsulation efficiency. However, the clinical use of CLs in cancer gene therapy is limited because of many uncertain factors in vivo. Extracellular barriers such as opsonization, rapid clearance by the reticuloendothelial system and poor tumor penetration, and intracellular barriers, including endosomal/lysosomal entrapped network and restricted diffusion to the nucleus, make CLs not the ideal vector for transferring extrinsic genes in the body. However, the obstacles in achieving productive therapeutic effects of nucleic acids can be addressed by tailoring the properties of CLs, which are influenced by lipid compositions and surface modification. This review focuses on the physiological barriers of CLs against cancer gene therapy and the effects of lipid compositions on governing transfection efficiency, and it briefly discusses the impacts of particle size, membrane charge density, and surface modification on the fate of CLs in vivo, which may provide guidance for their preclinical studies. Cationic liposomes (CLs) have been regarded as the most promising gene delivery vectors for decades with the advantages of excellent biodegradability, biocompatibility, and high nucleic acid encapsulation efficiency. However, the clinical use of CLs in cancer gene therapy is limited because of many uncertain factors in vivo. Extracellular barriers such as opsonization, rapid clearance by the reticuloendothelial system and poor tumor penetration, and intracellular barriers, including endosomal/lysosomal entrapped network and restricted diffusion to the nucleus, make CLs not the ideal vector for transferring extrinsic genes in the body. However, the obstacles in achieving productive therapeutic effects of nucleic acids can be addressed by tailoring the properties of CLs, which are influenced by lipid compositions and surface modification. This review focuses on the physiological barriers of CLs against cancer gene therapy and the effects of lipid compositions on governing transfection efficiency, and it briefly discusses the impacts of particle size, membrane charge density, and surface modification on the fate of CLs in vivo, which may provide guidance for their preclinical studies. Cationic liposomes (CLs) are near-spherical vesicles with a positive charge and are dominantly composed of cationic lipids that effectively condense nucleic acids1Parashar D. Rajendran V. Shukla R. Sistla R. Lipid-based nanocarriers for delivery of small interfering RNA for therapeutic use.Eur. J. Pharm. Sci. 2020; 142: 105159-105173Crossref PubMed Scopus (1) Google Scholar, 2Martínez-Negro M. Sánchez-Arribas N. Guerrero-Martínez A. Moyá M.L. Tros de Ilarduya C. Mendicuti F. Aicart E. Junquera E. A non-viral plasmid DNA delivery system consisting on a lysine-derived cationic lipid mixed with a fusogenic lipid.Pharmaceutics. 2019; 11: 632-648Crossref Scopus (1) Google Scholar, 3Blakney A.K. McKay P.F. Yus B.I. Aldon Y. Shattock R.J. Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA.Gene Ther. 2019; 26: 363-372Crossref PubMed Scopus (22) Google Scholar, 4Gao Y.-G. Liu F.-L. Lu F.-H. Alam U. Tang Q. Huang J.-W. Lu Z.-L. [12]aneN3-based single aliphatic chain modified cationic lipids as gene delivery vectors.Tetrahedron. 2019; 75: 658-664Crossref Scopus (1) Google Scholar such as plasmid DNA (pDNA), messenger RNA (mRNA), or small interfering RNA (siRNA) via electrostatic interactions5Monpara J. Velga D. Verma T. Gupta S. Vavia P. Cationic cholesterol derivative efficiently delivers the genes: in silico and in vitro studies.Drug Deliv. Transl. Res. 2019; 9: 106-122Crossref PubMed Scopus (4) Google Scholar to form complexes called “lipoplexes.” Based on the fact that genes have been revealed to be involved in the development of cancer,6Wu B. Zhang L. Yu Y. Lu T. Zhang Y. Zhu W. Song Q. Lv C. Guo J. Tian Y. Deng N. miR-6086 inhibits ovarian cancer angiogenesis by downregulating the OC2/VEGFA/EGFL6 axis.Cell Death Dis. 2020; 11: 345Crossref PubMed Scopus (1) Google Scholar,7Lu T. Wu B. Yu Y. Zhu W. Zhang S. Zhang Y. Guo J. Deng N. Blockade of ONECUT2 expression in ovarian cancer inhibited tumor cell proliferation, migration, invasion and angiogenesis.Cancer Sci. 2018; 109: 2221-2234Crossref PubMed Scopus (21) Google Scholar CLs have been extensively studied in cancer gene therapy and have shown potential clinical success in different tumors (Table 1). In general, the selection of CLs as gene carriers is attributed to their permanent positive charge, which promotes their stronger interaction with negatively charged substances such as nucleic acid, cell membrane, and endosomal membrane. In addition, CLs can be adjusted to obtain appropriate physical and chemical properties, such as size and tumor targeting, so as to obtain good pharmacokinetic properties in vivo. However, despite the good performance showed in in vitro studies, cationic lipid-based nucleic acid therapies in clinical trials are less than satisfactory because of the complicated biological environment.8Buck J. Grossen P. Cullis P.R. Huwyler J. Witzigmann D. Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery.ACS Nano. 2019; 13: 3754-3782Crossref PubMed Scopus (56) Google Scholar Most clinical trials of cationic liposomal delivery systems for cancer gene therapy have been approved (Table 2), but most are still in phase I or even discontinued.Table 1The Preclinical Studies of Cancer Gene Therapy Involving LipoplexesNameDrugCarrier ComponentsDiameter (nm)DiseaseReferencesT7-LPCEGFR siRNADOTAP/DOPE/Chol, 1:1:1 n/n, 5% T7-PEG-DSPE83glioma185Wei L. Guo X.Y. Yang T. Yu M.Z. Chen D.W. Wang J.C. Brain tumor-targeted therapy by systemic delivery of siRNA with transferrin receptor-mediated core-shell nanoparticles.Int. J. Pharm. 2016; 510: 394-405Crossref PubMed Scopus (0) Google ScholarPEGylated DC-Chol/DOPE cationic liposomesKSP siRNADC-Chol/DOPE/mPEG-2000-DSPE, 195:195:1 n/n102ovarian cancer47Lee J. Ahn H.J. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery carrier for ovarian cancer therapy.Biochem. Biophys. Res. Commun. 2018; 503: 1716-1722Crossref PubMed Scopus (0) Google ScholarDLPPIL-22BP mRNADOTAP/Chol, 1:1 n/n157colon cancer186Zhang R. Men K. Zhang X. Huang R. Tian Y. Zhou B. Yu C. Wang Y. Ji X. Hu Q. Yang L. Delivery of a modified mRNA encoding IL-22 binding protein (IL-22BP) for colon cancer gene therapy.J. Biomed. Nanotechnol. 2018; 14: 1239-1251Crossref PubMed Scopus (0) Google ScholarpegSA lipoplexesBMP-9 pDNAfSA/HSPC/DOPE/DSPE-mPEG-2000/Chol<100osteoporosis187Vhora I. Lalani R. Bhatt P. Patil S. Patel H. Patel V. Misra A. Colloidally stable small unilamellar stearyl amine lipoplexes for effective BMP-9 gene delivery to stem cells for osteogenic differentiation.AAPS PharmSciTech. 2018; 19: 3550-3560Crossref PubMed Scopus (11) Google ScholarFRα-targeted liposomesmatrix protein pDNADOTAP/Chol/mPEG-suc-Chol/F-PEG-suc-Chol, 50:45:4.75:0.25, n/n200ovarian cancer188He Z.Y. Deng F. Wei X.W. Ma C.C. Luo M. Zhang P. Sang Y.X. Liang X. Liu L. Qin H.X. et al.Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplex.Sci. Rep. 2016; 6: 23764Crossref PubMed Scopus (22) Google ScholarHA lipoplexesCD44 siRNAHA-DOPE/DE, 1:1 w/w230lung cancer189Leite Nascimento T. Hillaireau H. Vergnaud J. Rivano M. Deloménie C. Courilleau D. Arpicco S. Suk J.S. Hanes J. Fattal E. Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model.Int. J. Pharm. 2016; 514: 103-111Crossref PubMed Scopus (15) Google Scholar2X3-DOPE/FC liposomesMDR1 siRNA2X3/DOPE, 1:2 n/n60squamous carcinoma171Kabilova T.O. Shmendel E.V. Gladkikh D.V. Chernolovskaya E.L. Markov O.V. Morozova N.G. Maslov M.A. Zenkova M.A. Targeted delivery of nucleic acids into xenograft tumors mediated by novel folate-equipped liposomes.Eur. J. Pharm. Biopharm. 2018; 123: 59-70Crossref PubMed Scopus (8) Google ScholarHA-P-LPshRNA mRIP3-pDNADOTAP/DOPE/PEG-DSPE/Chol290colon cancer158Zhang L. Liu S. Liu H. Yang C. Jiang A. Wei H. Sun D. Cai Z. Zheng Y. Versatile cationic liposomes for RIP3 overexpression in colon cancer therapy and RIP3 downregulation in acute pancreatitis therapy.J. Drug Target. 2020; 28: 627-642Crossref PubMed Scopus (0) Google ScholarCL-siSOX2SOX2 siRNADOTAP/DPPC/DSPE-mPEG-2000, 2:3:2 n/n93lung cancer190Andey T. Bora-Singhal N. Chellappan S.P. Singh M. Cationic lipoplexes for treatment of cancer stem cell-derived murine lung tumors.Nanomedicine (Lond.). 2019; 18: 31-43Crossref PubMed Scopus (2) Google ScholarDACCCD31 siRNAAtuFECT01/Chol/mPEG-2000-DSPE, 70:29:1 n/n~70lung cancer191Fehring V. Schaeper U. Ahrens K. Santel A. Keil O. Eisermann M. Giese K. Kaufmann J. Delivery of therapeutic siRNA to the lung endothelium via novel lipoplex formulation DACC.Mol. Ther. 2014; 22: 811-820Abstract Full Text Full Text PDF PubMed Scopus (59) Google ScholarLiposome-siRNA nanocomplexSTAT3 siRNA, curcuminDOTAP/DOPE/sodium cholate/C6 ceramide, 50:30:10:10 w/w157skin cancer192Jose A. Labala S. Venuganti V.V. Co-delivery of curcumin and STAT3 siRNA using deformable cationic liposomes to treat skin cancer.J. Drug Target. 2017; 25: 330-341Crossref PubMed Scopus (21) Google ScholarEGFR, epidermal growth factor receptor; Chol, cholesterol; DSPE, 1,2-distearoyl-sn-glycero-3-phosphorylethanolamine; KSP, kinesin spindle protein; IL-22BP, interleukin-22 binding protein; pegSA, PEGylated stearyl amine; BMP-9, bone morphogenetic protein-9; FRα, folate receptor α; suc, succinyl; HA, hyaluronic acid; DE, [2-(2-3-didodecyloxypropyl)hydroxyethyl]ammonium bromide; 2X3, 1,26-bis(cholest-5-en-3β-yloxycarbonylamino)-7,11,16,20-tetraazahexacosan tetrahydrochloride; FC liposomes, folate-containing lipoconjugate liposomes; SOX2, SRY HMG-box 2; AtuFECT01, β-l-arginyl-2,3-l-diaminopropionic acid-N-palmityl-N-oleyl-amide trihydrochloride; DLPP, DOTAP liposome-protamine complex; CD31, platelet endothelial cell adhesion molecule-1; STAT3, signal transducer and activator of transcription 3; n/n, molar ratio; w/w, weight ratio. Open table in a new tab Table 2Cationic Liposomal Delivery System for Cancer Gene Therapy in Clinical TrialsNameDrugCarrier ComponentsAdministration RouteConditionClinicalTrials.gov Identifier (Phase)Sponsor and/or AffiliationsFirst PostedAtu027PKN3 siRNAAtuFECT01-DPhyPE/DSPE-PEG-2000i.v.pancreatic cancerNCT01808638 (I/II)Silence Therapeutics2013SGT-94RB94 pDNADOTAP/DOPEi.v.solid tumorsNCT01517464 (I)Synergene Therapeutics2012SGT-53HWTp53 pDNA, PD1 antibodyDOTAP/DOPEi.v.glioblastoma, solid tumors, pancreatic cancerNCT02340156 (II)Synergene Therapeutics2015NCT02340117 (II)Lipo-MERIT(NY-ESO-1, MAGE-A3, tyrosinase and TPTE) RNAsDOTMA/DOPEi.v.stage IIIB–IV melanomaNCT02410733 (I)Biopharmaceutical New Technologies2015Tusc2-nanoparticlesTusc2 pDNADOTAP/Choli.v.lung cancerNCT01455389 (I/II)MD Anderson Cancer Center2011Liposomal-DNA complexesinterleukin-2 pDNADOTMA/Choli.t.head and neck cancerNCT00006033 (II)H. Lee Moffitt Cancer Center and Research Institute2004DC-Chol liposomesEGFR antisense DNADC-Choli.t.head and neck cancerNCT00009841 (I)University of Pittsburgh2004pbi-shRNA STMN1 lipoplexesbi-shRNA-stathmin 1 pDNADOTAP/Choli.t.solid tumorsNCT01505153 (I)Gradalis2012IGTM-101(HSTK, cIFNβ, hIL-2, hGM-CSF) pDNADMRIE/DOPEintratumoral/peritumoral injectionmelanomaNCT03338777 (I) terminatedaFailure to achieve primary objective, terminated at 2020.Hospital Italiano de Buenos Aires2017Source: https://clinicaltrials.gov. PKN3, protein kinase N3; DPhyPE, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine; RB94, an N-terminal truncated retinoblastoma protein; HWTp53, human wild-type tumor protein 53; PD1, programmed cell death-1; NY-ESO-1, New York esophageal squamous cell carcinoma 1; MAGE-A3 melanoma antigen family A3; TPTE, transmembrane phosphatase with tensin homology; Tusc2, tumor suppressor candidate 2; STMN1, stathmin 1; DOTMA, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride; HSTK, herpes simplex thymidine kinase; cIFNβ, canine interferon β; hIL-2, human interleukin-2; hGM-CSF, human granulocyte-macrophage colony-stimulating factor; DMRIE, 1,2-dimyristyl oxypropyl-3-dimethyl-hydroxyethylammonium bromide; i.v., intravenous; i.t., intratumoral.a Failure to achieve primary objective, terminated at 2020. Open table in a new tab EGFR, epidermal growth factor receptor; Chol, cholesterol; DSPE, 1,2-distearoyl-sn-glycero-3-phosphorylethanolamine; KSP, kinesin spindle protein; IL-22BP, interleukin-22 binding protein; pegSA, PEGylated stearyl amine; BMP-9, bone morphogenetic protein-9; FRα, folate receptor α; suc, succinyl; HA, hyaluronic acid; DE, [2-(2-3-didodecyloxypropyl)hydroxyethyl]ammonium bromide; 2X3, 1,26-bis(cholest-5-en-3β-yloxycarbonylamino)-7,11,16,20-tetraazahexacosan tetrahydrochloride; FC liposomes, folate-containing lipoconjugate liposomes; SOX2, SRY HMG-box 2; AtuFECT01, β-l-arginyl-2,3-l-diaminopropionic acid-N-palmityl-N-oleyl-amide trihydrochloride; DLPP, DOTAP liposome-protamine complex; CD31, platelet endothelial cell adhesion molecule-1; STAT3, signal transducer and activator of transcription 3; n/n, molar ratio; w/w, weight ratio. Source: https://clinicaltrials.gov. PKN3, protein kinase N3; DPhyPE, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine; RB94, an N-terminal truncated retinoblastoma protein; HWTp53, human wild-type tumor protein 53; PD1, programmed cell death-1; NY-ESO-1, New York esophageal squamous cell carcinoma 1; MAGE-A3 melanoma antigen family A3; TPTE, transmembrane phosphatase with tensin homology; Tusc2, tumor suppressor candidate 2; STMN1, stathmin 1; DOTMA, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride; HSTK, herpes simplex thymidine kinase; cIFNβ, canine interferon β; hIL-2, human interleukin-2; hGM-CSF, human granulocyte-macrophage colony-stimulating factor; DMRIE, 1,2-dimyristyl oxypropyl-3-dimethyl-hydroxyethylammonium bromide; i.v., intravenous; i.t., intratumoral. The efficiency of CLs in gene delivery is affected by many factors in vivo and may not closely correspond to the studies in vitro.9Hattori Y. Nakamura M. Takeuchi N. Tamaki K. Shimizu S. Yoshiike Y. Taguchi M. Ohno H. Ozaki K.I. Onishi H. Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex.J. Drug Target. 2019; 27: 217-227Crossref PubMed Scopus (15) Google Scholar,10Sercombe L. Veerati T. Moheimani F. Wu S.Y. Sood A.K. Hua S. Advances and challenges of liposome assisted drug delivery.Front. Pharmacol. 2015; 6: 286-299Crossref PubMed Scopus (666) Google Scholar First, CLs can elicit opsonization after intravenous administration.11Digiacomo L. Pozzi D. Palchetti S. Zingoni A. Caracciolo G. Impact of the protein corona on nanomaterial immune response and targeting ability.Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2020; 12: e1615Crossref PubMed Scopus (2) Google Scholar CLs pick up plasma protein such as serum albumin, complements, immunoglobulins (Igs), and apolipoproteins to form a corona layer on their surface, providing them with a totally new biological identity that will dramatically alter their fates in vivo.12Francia V. Yang K. Deville S. Reker-Smit C. Nelissen I. Salvati A. Corona composition can affect the mechanisms cells use to internalize nanoparticles.ACS Nano. 2019; 13: 11107-11121Crossref PubMed Scopus (41) Google Scholar,13Digiacomo L. Giulimondi F. Mahmoudi M. Caracciolo G. Effect of molecular crowding on the biological identity of liposomes: an overlooked factor at the bio-nano interface.Nanoscale Adv. 2019; 1: 2518-2522Crossref Google Scholar Meanwhile, the reticuloendothelial system (RES) will first play the role of eliminating aliens to remove CLs from the blood circulation, and the inappropriate size and excessive positive charge of CLs accelerate this process.10Sercombe L. Veerati T. Moheimani F. Wu S.Y. Sood A.K. Hua S. Advances and challenges of liposome assisted drug delivery.Front. Pharmacol. 2015; 6: 286-299Crossref PubMed Scopus (666) Google Scholar,14Vakili-Ghartavol R. Jaafari M.R. Nikpoor A.R. Rezayat S.M. Docetaxel delivery using folate-targeted liposomes: in vitro and in vivo studies.Nanomed. J. 2020; 7: 108-114Google Scholar,15Zahednezhad F. Saadat M. Valizadeh H. Zakeri-Milani P. Baradaran B. Liposome and immune system interplay: challenges and potentials.J. Control. Release. 2019; 305: 194-209Crossref PubMed Scopus (11) Google Scholar In addition, even if they manage to escape the RES trap and extravasate from vasculatures to the tumor tissues, particle characteristics determine whether they can successfully penetrate from the complex tumor environment into tumor cells, followed by effective ingestion via efficient internalization. Besides, endosomal/lysosomal entrapment is another obstacle for CLs to deliver genes to cytoplasm,16Bruininks B.M.H. Souza P.C.T. Ingolfsson H. Marrink S.-J.J. A molecular view on the escape of lipoplexed DNA from the endosome.eLife. 2020; 9: 52012-52028Crossref Scopus (1) Google Scholar, 17Bus T. Traeger A. Schubert U.S. The great escape: how cationic polyplexes overcome the endosomal barrier.J. Mater. Chem. B Mater. Biol. Med. 2018; 6: 6904-6918Crossref PubMed Google Scholar, 18Wang B. Zhao R.M. Zhang J. Liu Y.H. Huang Z. Yu Q.Y. Yu X.Q. Rigid aromatic linking moiety in cationic lipids for enhanced gene transfection efficiency.Eur. J. Med. Chem. 2017; 136: 585-595Crossref PubMed Scopus (7) Google Scholar which is greatly affected by the fusogenic capability of CLs.19Bae Y.U. Huh J.W. Kim B.K. Park H.Y. Seu Y.B. Doh K.O. Enhancement of liposome mediated gene transfer by adding cholesterol and cholesterol modulating drugs.Biochim. Biophys. Acta. 2016; 1858: 3017-3023Crossref PubMed Scopus (10) Google Scholar Furthermore, the reticular cytoskeletal network and the macromolecular crowding in the cytoplasm are not conducive to the transport of lipoplexes or DNA to the nucleus.20Etoc F. Balloul E. Vicario C. Normanno D. Liße D. Sittner A. Piehler J. Dahan M. Coppey M. Non-specific interactions govern cytosolic diffusion of nanosized objects in mammalian cells.Nat. Mater. 2018; 17: 740-746Crossref PubMed Scopus (44) Google Scholar,21Grady M.E. Parrish E. Caporizzo M.A. Seeger S.C. Composto R.J. Eckmann D.M. Intracellular nanoparticle dynamics affected by cytoskeletal integrity.Soft Matter. 2017; 13: 1873-1880Crossref PubMed Google Scholar Therefore, even though CLs have been considered to be the most promising nanocarriers for cancer gene therapy, gene delivery to target sites is bumpy, because CLs, as invaders, face a series of events such as opsonization, rapid clearance by the RES, poor tumor penetration, cellular uptake, and lysosomal degradation, resulting in therapeutic failure in the body. The intracorporal fates of CLs are not only affected by the physiological environment but also by the physiochemical properties of CLs, while the latter are primarily determined by lipid compositions.8Buck J. Grossen P. Cullis P.R. Huwyler J. Witzigmann D. Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery.ACS Nano. 2019; 13: 3754-3782Crossref PubMed Scopus (56) Google Scholar,22Foteini P. Pippa N. Naziris N. Demetzos C. Physicochemical study of the protein-liposome interactions: influence of liposome composition and concentration on protein binding.J. Liposome Res. 2019; 29: 313-321Crossref PubMed Scopus (10) Google Scholar, 23Li T. He J. Horvath G. Próchnicki T. Latz E. Takeoka S. Lysine-containing cationic liposomes activate the NLRP3 inflammasome: Effect of a spacer between the head group and the hydrophobic moieties of the lipids.Nanomedicine (Lond.). 2018; 14: 279-288Crossref PubMed Scopus (0) Google Scholar, 24Xia Y. Tian J. Chen X. Effect of surface properties on liposomal siRNA delivery.Biomaterials. 2016; 79: 56-68Crossref PubMed Scopus (102) Google Scholar CLs are usually composed of the cationic lipids and neutral helper lipids such as cholesterol, dioleoyl phosphatidylethanolamine (DOPE), and polyethylene glycol (PEG)-lipid, among others. Notably, the molecular structure of cationic lipid and the ability of neutral helper lipid to trigger fusion are of great importance to govern transfection efficiency (TE).9Hattori Y. Nakamura M. Takeuchi N. Tamaki K. Shimizu S. Yoshiike Y. Taguchi M. Ohno H. Ozaki K.I. Onishi H. Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex.J. Drug Target. 2019; 27: 217-227Crossref PubMed Scopus (15) Google Scholar,25Sato Y. Hashiba K. Sasaki K. Maeki M. Tokeshi M. Harashima H. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.J. Control. Release. 2019; 295: 140-152Crossref PubMed Scopus (22) Google Scholar, 26Cheng X. Lee R.J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.Adv. Drug Deliv. Rev. 2016; 99: 129-137Crossref PubMed Scopus (82) Google Scholar, 27Santiwarangkool S. Akita H. Nakatani T. Kusumoto K. Kimura H. Suzuki M. Nishimura M. Sato Y. Harashima H. PEGylation of the GALA peptide enhances the lung-targeting activity of nanocarriers that contain encapsulated siRNA.J. Pharm. Sci. 2017; 106: 2420-2427Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar It has been reported that TE is highly correlated with nanoparticle size and surface charge, both of which are affected by lipid composition.28Wu Y. Xiong Y. Wang L. Zhou Q. Li L. Levkin P.A. Davidson G. Gao L. Deng W. Development of new self-assembled cationic amino liposomes for efficient gene delivery.Biomater. Sci. 2020; 8: 3021-3025Crossref PubMed Google Scholar,29Wu Y. Li L. Chen Q. Su Y. Levkin P.A. Davidson G. Single-tailed lipidoids enhance the transfection activity of their double-tailed counterparts.ACS Comb. Sci. 2016; 18: 43-50Crossref PubMed Scopus (3) Google Scholar Additionally, the active targeting and appropriate characteristics of CLs can also be obtained by simply tailoring the lipid compositions, which are crucial to the outperformance of CLs in the body. Therefore, the rational design of CLs requires a full understanding of the relationship between lipid composition and therapeutic outcome. The clinical research of lipoplex-based therapeutic agents in cancer treatment has made slow progress in the last two decades due to the complicated environment and poor therapeutic outcome in the human body. Therefore, understanding the factors affecting CL-based gene therapy is crucial for the design of efficient and clinically applicable gene delivery vectors. Once administered intravenously, the plasma proteins will adsorb to CLs or lipoplexes and eventually form a so called “protein corona” (PC) at their surface that can specifically bind to phagocytes (Figure 1).30Zhang Y. Wu J.L.Y. Lazarovits J. Chan W.C.W. An analysis of the binding function and structural organization of the protein corona.J. Am. Chem. Soc. 2020; 142: 8827-8836Crossref PubMed Google Scholar,31Xiao W. Gao H. The impact of protein corona on the behavior and targeting capability of nanoparticle-based delivery system.Int. J. Pharm. 2018; 552: 328-339Crossref PubMed Scopus (44) Google Scholar The absorption of complement protein activates the complement system,32Capriotti A.L. Caracciolo G. Caruso G. Foglia P. Pozzi D. Samperi R. Laganà A. DNA affects the composition of lipoplex protein corona: a proteomics approach.Proteomics. 2011; 11: 3349-3358Crossref PubMed Scopus (0) Google Scholar while Ig promotes the opsonization of CLs,33Szebeni J. Moghimi S.M. Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions.J. Liposome Res. 2009; 19: 85-90Crossref PubMed Scopus (0) Google Scholar with both resulting in rapid clearance of CLs. However, based on the immunogenicity of CLs, some researchers have exploited this property of liposomes to target immune cells such as tumor-associated macrophages and dendritic cells.34Roces C.B. Khadke S. Christensen D. Perrie Y. Scale-independent microfluidic production of cationic liposomal adjuvants and development of enhanced lymphatic targeting strategies.Mol. Pharm. 2019; 16: 4372-4386Crossref PubMed Scopus (10) Google Scholar,35Uemura Y. Naoi T. Kanai Y. Kobayashi K. The efficiency of lipid nanoparticles with an original cationic lipid as a siRNA delivery system for macrophages and dendritic cells.Pharm. Dev. Technol. 2019; 24: 263-268Crossref PubMed Scopus (7) Google Scholar In antitumor immunotherapy or vaccination, CLs can also serve as an attractive adjuvant36Li S. Yang Y. Lin X. Li Z. Ma G. Su Z. Zhang S. Biocompatible cationic solid lipid nanoparticles as adjuvants effectively improve humoral and T cell immune response of foot and mouth disease vaccines.Vaccine. 2020; 38: 2478-2486Crossref PubMed Scopus (0) Google Scholar in addition to its carrier function, because CLs themselves can elicit the release of cytokine and the activation of natural killer (NK) cells, resulting in a greatly enhanced pro-inflammatory response around the tumor tissue.37Audouy S.A.L. de Leij L.F.M.H. Hoekstra D. Molema G. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.Pharm. Res. 2002; 19: 1599-1605Crossref PubMed Scopus (161) Google Scholar,38De Serrano L.O. Burkhart D.J. Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines.J. Nanobiotechnology. 2017; 15: 83-105Crossref PubMed Scopus (15) Google Scholar Despite this, the impacts of PC on CLs are sometimes fatal, such as aggregation, charge neutrality, and size enlargement, leading to their instability and drug release before cell uptake.39Digiacomo L. Cardarelli F. Pozzi D. Palchetti S. Digman M.A. Gratton E. Capriotti A.L. Mahmoudi M. Caracciolo G. An apolipoprotein-enriched biomolecular corona switches the cellular uptake mechanism and trafficking pathway of lipid nanoparticles.Nanoscale. 2017; 9: 17254-17262Crossref PubMed Google Scholar,40Digiacomo L. Pozzi D. Amenitsch H. Caracciolo G. Impact of the biomolecular corona on the structure of PEGylated liposomes.Biomater. Sci. 2017; 5: 1884-1888Crossref PubMed Google Scholar Meanwhile, the active moieties of ligand-modified CLs may also be shielded after opsonization.41Mahmoudi M. Bertrand N. Zope H. Farokhzad O.C. Emerging understanding of the protein corona at the nano-bio interfaces.Nano Today. 2016; 11: 817-832Crossref Scopus (124) Google Scholar Several recent findings have confirmed that the decoration of PC on nanocarriers could alter their internalization mechanism and hence intracellular trafficking fate.12Francia V. Yang K. Deville S. Reker-Smit C. Nelissen I. Salvati A. Corona composition can affect the mechanisms cells use to internalize nanoparticles.ACS Nano. 2019; 13: 11107-11121Crossref PubMed Scopus (41) Google Scholar,39Digiacomo L. Cardarelli F. Pozzi D. Palchetti S. Digman M.A. Gratton E. Capriotti A.L. Mahmoudi M. Caracciolo G. An apolipoprotein-enriched biomolecular corona switches the cellular uptake mechanism and trafficking pathway of lipid nanoparticles.Nanoscale. 2017; 9: 17254-17262Crossref PubMed Google Scholar,42Palchetti S. Digiacomo L. Giulimondi F. Pozzi D. Peruzzi G. Ferri G. Amenitsch H. Cardarelli F. Mahmoudi M. Caracciolo G. A mechanistic explanation of the inhibitory role of the protein corona on liposomal gene expression.Biochim. Biophys. Acta Biomembr. 2020; 1862: 183159-183171Crossref PubMed Scopus (0) Google Scholar All of these changes will produce different clinical effects than expected, which is one of the reasons for the little clinical progress of nanocarriers in recent decades. Importantly, however, note that the isolated serum or plasma is not completely consistent with the actual physiological environment, which means that in vitro experiments on liposomes cannot be fully used to predict their behavioral changes in vivo.43Walkey C.D. Chan W.C. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment.Chem. Soc. Rev. 2012; 41: 2780-2799Crossref PubMed Scopus (0) Google Scholar Many efforts have been made to avoid the negative effects of corona, among which PEGylation44Seraj S. Lee J. Ahn H.J. Systemic delivery of Eg5 shRNA-expressing plasmids using PEGylated DC-Chol/DOPE cationic liposome: long-term silencing and anticancer effects in vivo.Biochem. Pharmacol. 2019; 166: 192-202Crossref PubMed Scopus (0) Google Scholar,45Sasayama Y. Hasegawa M. Taguchi E. Kubota K. Kuboyama T. Naoi T. Yabuuchi H. Shimai N. Asano M. Tokunaga A. et al.In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors.J. Control. Release. 2019; 311–312: 245-256Crossref PubMed Scopus (2) Google Scholar is more effective and commonly used. Attaching PEG chains creates a shielding layer at the surface of CLs and hence the formation of steric barriers and the reduction of exposed charges,46Majzoub R.N. Chan C.-L. Ewert K.K. Silva B.F.B. Liang K.S. Jacovetty E.L. Carragher B. Potter C.S. Safinya C.R. Uptake and transfection efficiency of PEGylated cationic liposome-DNA complexes with and without RGD-tagging.Biomaterials. 2014; 35: 4996-5005Crossref PubMed Scopus (61) Google Scholar resulting in less formation of PC and extension of circulation time in the body.47Lee J. Ahn H.J. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery carrier for ovarian canc

Recent Progress in Multidrug Delivery to Cancer Cells by Liposomes

Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines

Barriers and Strategies of Cationic Liposomes for Cancer Gene Therapy

RGD-modified PEG-PAMAM-DOX Conjugate: in Vitro and in Vivo Targeting to Both Tumor Neovascular Endothelial Cells and Tumor Cells.

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Obstacles Impeding the Development of Nanocarriers for Anticancer Drugs

Linear-like polypeptide-based micelle with pH-sensitive detachable PEG to deliver dimeric camptothecin for cancer therapy

Promoting the bench-to-bedside translation of nanomedicines

Drug Delivery: Gel–Liposome-Mediated Co-Delivery of Anticancer Membrane-Associated Proteins and Small-Molecule Drugs for Enhanced Therapeutic Efficacy (adv. Funct. Mater. 16/2014)

Drug Delivery: Gel–Liposome‐Mediated Co‐Delivery of Anticancer Membrane‐Associated Proteins and Small‐Molecule Drugs for Enhanced Therapeutic Efficacy (Adv. Funct. Mater. 16/2014)

Endosome-mimicking Nanogels for Targeted Drug Delivery

A Nanomedicine Composed of Polymer- ss -DOX and Polymer-Ce6 Prodrugs with Monoclonal Antibody Targeting Effect for Anti-tumor Chemo-Photodynamic Synergetic Therapy

Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer

Photothermal-responsive nanosized hybrid polymersome as versatile therapeutics codelivery nanovehicle for effective tumor suppression.

Targeted PHA Microsphere-Loaded Triple-Drug System with Sustained Drug Release for Synergistic Chemotherapy and Gene Therapy

Ginsenoside Rh2-Based Multifunctional Liposomes for Advanced Breast Cancer Therapy

Folate-decorated PEGylated Triblock Copolymer As a Ph/reduction Dual-Responsive Nanovehicle for Targeted Intracellular Co-Delivery of Doxorubicin and Bcl-2 Sirna.

Gene Reprogramming Armed Macrophage Membrane-Camouflaged Nanoplatform Enhances Bionic Targeted Drug Delivery to Solid Tumor for Synergistic Therapy

Prodrugs Forming High Drug Loading Multifunctional Nanocapsules for Intracellular Cancer Drug Delivery.

Gene/paclitaxel Co-Delivering Nanocarriers Prepared by Framework-Induced Self-Assembly for the Inhibition of Highly Drug-Resistant Tumors.

Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment